硕士生导师，中山大学百人计划引进人才

 

研究方向

卫生与药物经济学、医疗保险、真实世界研究、应用计量经济及药物流行病学

 

工作经历

2019/04至今           中山大学公共卫生学院（深圳），副教授
2016/03-2019/04   美国安进公司 (Amgen Inc.) ，全球卫生经济学经理
2012/05-2016/03   南加州大学Schaeffer卫生政策与经济研究中心，研究助理

 

教育经历

2012/08-2016/03   南加州大学，药物与卫生经济系，博士
2010/08-2012/05   南加州大学，药物经济与政策系，硕士
2006/09-2010/07   暨南大学，药学、金融，理学学士及经济学学士

 

研究简介

副教授、硕士生导师。主要研究领域为卫生与药物经济学、医疗保险、真实世界证据等。以独立、第一或通讯作者在Health Economics、China Economic Review、PharmacoEconomics、Value in Health、Annals of Internal Medicine等英文期刊发表论文五十余篇。担任Health Economics Review（经济学SSCI Q1、卫生政策SSCI Q1）副主编、PharmacoEconomics（FMS管理学高质量国际期刊、ADBC列表A类期刊）编委等学术职务。主持各类项目二十余项。

 

讲授课程

本科：卫生经济学基础、卫生事业管理等

研究生：卫生经济学与计量经济学

 

承担课题及科研项目

国家自然科学基金（管理科学），青年基金项目，2021.01-2023.12，24万元，结题，主持

国家重点研发计划，基于真实世界的疫苗保护效果技术体系研究，2024.11-2027.10，18万元，在研，子任务负责人

广东省基础与应用基础研究基金（医学），企业联合基金面上项目，2022.01-2024.12，40万元，结题，主持

广东省基础与应用基础研究基金（管理科学），区域联合基金青年基金项目，2020.01-2022.12，10万元，结题，主持

 


代表性文章

 

(*代表通讯作者，#为共同第一作者)

 

1.Jiang Y. * The Spillover Effects of a City-Wide Global Budget and Case-Based Payment Reform on Inbound Non-Resident Patients. Health Economics. (2025).

 

2. Jiang, Y.*, Li, M., Jiang, S., Si, L., Gu, Y.* Patient Welfare Implications of Indication-specific Value-based Pricing of Multi-indication Drugs. Value in Health. (2023).

 

3. Jiang, Y.* & Ni, W. Impact of supplementary private health insurance on hospitalization and physical examination in China.China Economic Review. (2020). 

 

4. Cai, D., Shi, S., Jiang, S., Si, L., Wu, J.*, Jiang, Y.* Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life. European Journal of Health Economics. (2022).

 

5. Kang, M. #, Yi, Y. #, ... Jiang, Y.*, Tang, S.*, He, J.* Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China: A Cohort Study. Annals of Internal Medicine. (2022).

 

6. Jiang, Y.*#, Wen, J.#, Sun, J., Shu, Y. * Evaluating the Public Health and Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for Influenza Pandemic Control in China: A Cost-Effectiveness Analysis Using a Linked Dynamic Transmission–Economic Evaluation Model. PharmacoEconomics. (2024).

 

7. Jiang, Y.* & Ni, W. Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease. PharmacoEconomics. (2019). 

 

8. Jiang, Y.#, Sun, J.#, Huang, F.#, Xie, X., Wang, X., Wu, X., Jiang, M., Sun, Y., Liu, H., Gu, H., Lu, Q., Chen, X., Feng, T., Fang, S.*, Lu, J.*, Shu, Y.* Influenza Vaccine Effectiveness among Primary and Secondary School Students in Shenzhen during the 2023/24 Influenza Season. Emerging Microbes & Infections. (2025). 

 

9. Jiang, Y.#*, Ye, Z#, Chen, D., & Shu, Y*. Dual influenza and pneumococcal vaccination was associated with lower short-term risks of all-cause and acute respiratory hospitalizations among the elderly in Shenzhen, China: a retrospective cohort study. Emerging Microbes & Infections. (2020). 

 

10.Jiang, Y.*, McCombs, J. S., & Park, S. H. A Retrospective Cohort Study of Acute Kidney Injury Risk Associated with Antipsychotics. CNS drugs. (2017).

 

  • 其他第一作者/通讯作者论文列表

38. Wen J, Li M, Jiang Y*. Cost Effectiveness of Innovative Anti-Cancer Drugs and Reimbursement Decisions in China. Health Policy and Technology. (2023).

 

37. Jiang, Y.* & Ni, W. Performance of unanchored matching-adjusted indirect comparison (MAIC) for the evidence synthesis of single-arm trials with time-to-event outcomes. BMC Medical Research Methodology. (2020).

 

36. Yi, Y. # & Jiang, Y. #*A process to validate prognostic factors for unanchored matching-adjusted indirect comparison of single-arm trials in oncology: a proof-of-concept study. Journal of Comparative Effectiveness Research. (2025). 

 

35. Shi, S., Jiang, Y.*Does supplemental private health insurance incentivize household risky financial asset investment? Evidence from the China Household Financial Survey. International Journal of Health Economics and Management. (2022). 

 

34. Yi, Y. #, Liu, J. #, Zhang, Y. #, Zeng, B., Lin, L., Li, C., ... & Jiang, Y. * Effectiveness of Lanzhou Lamb Rotavirus Vaccine and RotaTeq Against Hospitalized Rotavirus Infections Among Children During 2020-2023 in Guangdong Province, China: A Test-Negative Case-Control Study. Infectious Diseases and Therapy. (2024). 

 

33. Jiang, Y.*, Jiang, S. & Ni, W. The burden of cardiovascular diseases associated with fine particulate matter in Beijing, China: an economic modelling study. BMJ Global Health. (2020). 

 

32. Jiang, Y.*, Cai, D., Chen, D. & Jiang, S. The cost-effectiveness of conducting three versus two reverse transcription-polymerase chain reaction tests for diagnosing and discharging people with COVID-19: evidence from the epidemic in Wuhan, China.BMJ Global Health. (2020).

 

31.Fang, B., Jiang, Y*. Impacts of the diagnosis-intervention packet reform on costs and healthcare resource utilization: evidence from Guangzhou, China. Health Economics Review. (2025).

 

30. Ni, W., Kunz, W.G., Goyal, M., Chen, L., Jiang, Y.* Quality of life and cost consequence of delays in endovascular treatment for acute ischemic stroke in China. Health Economics Review. (2022).

 

29. Jiang, Y.* & Ni, W. Risk selection into supplemental private health insurance in China. Health Economics Review. (2019).

 

28. Jiang, Y.*, Li. L., Projections of functional dependence among the late middle-aged and older population from 2018-2048 in China: a dynamic microsimulation. Global Health Research and Policy. (2024).

 

27. Jiang, Y., Jiang, S., Li, L. et al. Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis. Applied Health Economics and Health Policy. (2023).

 

26. Papaioannou, A., Adachi, J. D., Berger, C., Jiang, Y.*, Barron, R., McGinley, J. S., ... & Ioannidis, G. Testing a theoretical model of imminent fracture risk in elderly women: an observational cohort analysis of the Canadian Multicentre Osteoporosis Study. Osteoporosis International. (2020).

 

25. Ni, W. & Jiang, Y.* Evaluation on the Cost-effective Threshold of Osteoporosis Treatment on Elderly Women in China Using Discrete Event Simulation Model. Osteoporosis International. (2017).

 

24. Jiang, Y.*, Cai, D., Shi, S., Indirect comparisons via sorafenib for the comparative effectiveness of two PD-1/PD-L1 inhibitors to treat advanced hepatocellular carcinoma patients without prior systemic therapies. Clinical Epidemiology. (2022).

 

23. Li, M., Fang, B., Gu, H., & Jiang, Y. * EQ-5D-5L and SF-6Dv2 health utilities scores of diffuse large B-cell lymphoma patients in China. Health and Quality of Life Outcomes. (2024).

 

22. Jiang, S., Cai, D., Chen, D., Jiang, Y*. An Analysis of Life-Year Lost Due to COVID-19 - 34 Countries, December 2019-March 2021. China CDC Wkly. (2022).

 

21. Jiang, S., Chen, Z., Wu, J., Zang, X., & Jiang, Y. *Addressing Methodological and Ethical Issues in Practicing Health Economic Evaluation in China. Journal of Global Health. (2020). 

 

20. Jiang, Y.* & Ni, W. Healthcare Utilization and Treatment Persistence Associated with Oral Paliperidone and Lurasidone in Schizophrenia Treatment. Journal of Managed Care Pharmacy. (2015).

 

19. Jiang, Y.* & Ni, W. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization. Pharmacotherapy. (2015).

 

18. Liu, G., # Yi, Y., # Sun, J., # Feng, H., Hu, B., Hu, W., Gu, H., Bu, R., Jiang, Y.* Association Between Follow-Up Visit Frequency, Medication Types Prescribed, and Glycemic Outcomes Among Diabetic Patients in China’s Basic Public Health Services Program: A Retrospective Cohort Study. BMJ Public Health. (2025). 

 

17. Ye, Z., Jiang, Y.*, The impact of a pilot integrated care model on the quality and costs of inpatient care among Chinese elderly: a difference-in-difference analysis of repeated cross-sectional data. Cost Effectiveness and Resource Allocation. (2022). 

 

16. Jiang, Y.* & Ni, W. Association Between Supplemental Private Health Insurance and Burden of Out-of-Pocket Healthcare Expenditure in China: A Novel Approach to Estimate Two-Part Model with Random Effects Using Panel Data. Risk Management & Healthcare Policy. (2020).

 

15. Jiang, Y.*,Lin, Y-F., Shi, S., Chen, D., Shu, Y.* Effects of baloxavir and oseltamivir antiviral therapy on the transmission of seasonal influenza in China: A mathematical modeling analysis. Journal of Medical Virology. (2022). 

 

14. Jiang, Y.*, Chen, D. Cai, D., Yi, Y. & Jiang, S. Effectiveness of remdesivir for the treatment of hospitalized Covid-19 persons: a network meta-analysis. Journal of Medical Virology. (2020).

 

13. Jiang, Y. *, Hu, W., Hu, B., Gu, H., Cui, Y., Zhao, X. Are quality-adjusted life years (QALYs) becoming more expensive? Evidence from economic evaluations of diabetic therapeutics. Expert Review of Pharmacoeconomics & Outcomes Research. (2025). https://doi.org/10.1080/14737167.2025.2451747

 

12. Jiang, Y.*, Cai, D., Shi, S. Economic evaluations of inactivated COVID-19 vaccines in six Western Pacific and South East Asian countries and regions: A modeling study. Infectious Disease Modelling. (2022). 

 

11. Jiang, Y.*, Cai, D., Chen, D., Jiang, S., Si, L., & Wu, J. Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios. British Journal of Clinical Pharmacology. (2021). 

 

10. Chen, D.#, Ye, Z.#, Pi, Z., Mizukami, S., Aoyagi, K., Jiang, Y.*. Cost-effectiveness of dual influenza and pneumococcal vaccination among the elderly in Shenzhen, China. Vaccine. (2021).

 

9. Jiang, Y., Liu, J., Chen, X., Yang, W., Jia, W., Wu, J.* Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-analysis. Advances in Therapy (2021).

 

8. Jiang, Y., Ni, W. & Wu, J.* Cost-effectiveness and Value-based Prices of the 9-valent Human Papillomavirus Vaccine for the Prevention of Cervical Cancer in China: An Economic Modelling Analysis. BMJ Open. (2019).

 

7. Jiang, Y.*, Ni, W. Factors Related to the Comparative Effectiveness of Clozapine in Patients with Schizophrenia. Journal of Comparative Effectiveness Research. (2019).

 

6. Jiang, Y.*, Ni, W. Estimates of Age-specific Diabetes Incidence among Men and Women in China Using Secondary Data Analysis. Diabetic Medicine. (2019).

 

5. Jiang, Y.* & Ni, W. Expected Lifetime Numbers, Risks, and Burden of Osteoporotic Fractures for 50-Year Old Chinese Women— a Discrete Event Simulation Incorporating FRAX. Journal of Bone and Mineral Metabolism. (2016).

 

4. Feng, H.#, Chen, J.#, Sun, J., Jiang, Y.* Impacts of COVID-19 vaccine boosters on clinical outcomes associated with the Omicron variant in China: A cross-sectional survey. Vaccine: X. (2024).

 

3. Chen. J., Jiang, Y.* Treatment Patterns of Traditional Chinese Medicine Formula Granules among Patients with Type 2 Diabetes. Integrative Medicine Reports. (2024).

 

2. Zhang, X., Wen, Y.J., Han, N. *, Jiang, Y.* The Effect of a Video-Assisted Health Education Program Followed by Peer Education on the Health Literacy of COVID-19 and Other Infectious Diseases Among School Children: Quasi-Randomized Controlled Trial. JMIR Human Factors. (2024).

 

1. Jiang, Y.*, Ni, W., McGinnis, J. Comparison of Health Services Use Associated with Ziprasidone and Olanzapine among Schizophrenia and Bipolar Disorder Patients in the USA. Clinical Drug Investigation. (2014).

 

其他论著

1.中华预防医学会流感疫苗保护效果真实世界研究共识专家组，舒跃龙*, 冯子健*, 蒋亚文*. 流行性感冒疫苗保护效果真实世界研究专家共识. 《中国疫苗和免疫》（2022）

 

兼职情况

　　中国药学会药物经济学专委会委员、国家医保局长期护理险专家库成员、中国医保研究会药物经济学专委会委员、中国疫苗行业协会疫苗经济学专委会委员、中国研究型医院学会药物经济学专委会委员、中国人体健康科技促进会药物政策研究工作委员会委员、中华预防医学会百日咳防控工作委员会委员、中国中医药研究促进会药物经济学专委会委员、中国健康促进与教育协会健康教育方法学研究分会委员、广东省药监局/卫健委“港澳药械通”评审专家、广东省医药价格协会药物价值评估专委会副主委、海南省医保局真实世界数据医保应用专家咨询委员会委员、广东省健康教育协会妇幼健康专委会副主委、深圳市乳腺癌防治联盟卫生经济学组副组长、深圳市卫生经济学会卫生统计专委会常委、《中国卫生经济》及《中国疫苗和免疫》编委等

 

招生信息

     招收硕士生2-3人/年，并接收本科生进行科研培训。欢迎有志于卫生与药物经济、真实世界数据、医疗保险等领域的来自流行病学、经济学、统计学、数学、管理学等相关专业的同学加入我们。